Swedish Orphan Biovitrum AB - Company Profile
Powered by 
All the sales intelligence you need on Swedish Orphan Biovitrum AB in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Swedish Orphan Biovitrum AB fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Swedish Orphan Biovitrum AB.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Swedish Orphan Biovitrum AB (Sobi) is an integrated biopharmaceutical company. It focuses on the development of products for the treatment of rare diseases. The company specializes in biotechnology with capabilities in protein biochemistry and biologics manufacturing. Its product portfolio focuses on hemophilia, immunology, specialty care, inflammation, and genetic and metabolic diseases. The company also provides treatment for conditions such as amyotrophic lateral sclerosis (ALS). It also manufactures and markets specialty products for rare diseases for partner companies. The company has an operational presence in Europe, the Middle East, North America, Russia, and Asia. Sobi is headquartered in Stockholm, Sweden
Headquarters
Sweden
Address
Norra Stationsgatan 93a, Stockholm, 11276
Website
www.sobi.com
Telephone
46 869 72000
No of Employees
2,119
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
SOBI (STO)
Revenue (2024)
$2.9B
8.5%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
-87.7%
(2024 vs 2023)
Market Cap*
$17.0B
Net Profit Margin (2024)
XYZ
-88.7%
(2024 vs 2023)
* As of and is in US$
Swedish Orphan Biovitrum AB premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Eftrenonacog Alfa | Alprolix |
| Pegcetacoplan | ALTUVOCT |
| Emapalumab | Aspaveli/Empaveli |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2026 | Contracts/Agreements | In August, the company entered into a partnership with Innate Pharma SA to enable initiation of the TELLOMAK-3 confirmatory Phase 3 study in cutaneous T-cell lymphoma. |
| 2026 | Acquisitions/Mergers/Takeovers | In February, the company completed the acquisition of Arthrosi Therapeutics Inc, a private late-stage biotechnology company. |
| 2026 | Regulatory Approval | In January, the company received approval from the European Commission for Aspaveli (pegcetacoplan) to treat patients with C3 glomerulopathy or primary immune-complex membranoproliferative glomerulonephritis in combination with a renin-angiotensin system inhibitor. |
Competitor Comparison
| Key Parameters | Swedish Orphan Biovitrum AB | BioMarin Pharmaceutical Inc | Recordati SpA | Probi AB | Hansa Biopharma AB |
|---|---|---|---|---|---|
| Headquarters | Sweden | United States of America | Italy | Sweden | Sweden |
| City | Stockholm | San Rafael | Milan | Lund | Lund |
| State/Province | Stockholm | California | - | - | - |
| No. of Employees | 2,119 | 3,221 | 4,693 | 157 | 131 |
| Entity Type | Public | Public | Public | Private | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| David Meek | Chairman | Executive Board | 2024 | 63 |
| Guido Oelkers | Chief Executive Officer | Senior Management | 2017 | 61 |
| Henrik Stenqvist | Chief Financial Officer | Senior Management | 2018 | 59 |
| Lydia Abad-Franch | Chief Medical Officer; Head - Medical Affairs; Head - Research & Development | Senior Management | 2020 | 55 |
| Norbert Oppitz | Head - International | Senior Management | 2017 | 59 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer